By some estimates, the cost of insulin has tripled in the last ten years, even though the medication has stayed the same.
Public outrage over high insulin prices, fueled by stories of diabetes patients dying because they couldn't afford their medication, is driving a new flurry of measures that aim to control or reduce prices for the drug.
It has been almost exactly two years since Jesse Lutgen died on Feb. 7, 2018, after losing his health insurance and not being able to afford insulin for his Type 1 diabetes. Lutgen's death is one of more than ten similar cases in the last three years—Americans who died from a health condition that is easily treatable with medications that used to be more affordable.
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
